GLP-1 receptor agonist medications designed for weight loss, exemplified by Ozempic, have left an indelible mark on the healthcare landscape. Globally, millions of patients have experienced substantial weight reduction through their use. This phenomenon has not only spurred innovation within the food industry, prompting the development of products tailored to complement these medications, but has also led insurance companies to delve deeply into researching the drugs' potential to lower mortality rates.

The mechanism of action for these drugs centers on appetite suppression and the deceleration of gastric emptying, thereby facilitating weight loss. Nonetheless, their utilization is not without drawbacks. Patients may encounter adverse effects, including gastrointestinal disturbances, muscle wasting, and an increased risk of osteoporosis. Furthermore, the prevalent off-label prescription of these medications underscores the critical importance of adhering strictly to medical guidance to ensure safe and effective use.